The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes
Abstract
UNLABELLED: We determined whether insulin therapy changes liver fat content (LFAT) or hepatic insulin sensitivity in type 2 diabetes. Fourteen patients with type 2 diabetes (age 51+/-2 yr, body mass index 33.1+/-1.4 kg/m2) treated with metformin alone received additional basal insulin for 7 mo. Liver fat (proton magnetic resonance spectroscopy), fat distribution (MRI), fat-free and fat mass, and whole body and hepatic insulin sensitivity (6-h euglycemic hyperinsulinemic clamp combined with infusion of [3-(3)H]glucose) were measured. The insulin dose averaged 75+/-10 IU/day (0.69+/-0.08 IU/kg, range 24-132 IU/day). Glycosylated hemoglobin A1c (Hb A1c) decreased from 8.9+/-0.3 to 7.4+/-0.2% (P<0.001). Whole body insulin sensitivity increased from 2.21+/-0.38 to 3.08+/-0.40 mg/kg fat-free mass (FFM).min (P<0.05). This improvement could be attributed to enhanced suppression of hepatic glucose production (HGP) by insulin (HGP 1.04+/-0.28 vs. 0.21+/-0.19 mg/kg FFM.min, P<0.01). The percent suppression of HGP by insulin increased from 72+/-8 to 105+/-11% (P<0.01). LFAT decreased from 17+/-3 to 14+/-3% (P<0.05). The change in LFAT was significantly correlated with that in hepatic insulin sensitivity (r=0.56, P<0.05). Body weight increased by 3.0+/-1.1 kg (P<0.05). Of this, 83% was due to an increase in fat-free mass (P<0.01). Fat distribution and serum adiponectin concentrations remained unchanged while serum free fatty acids decreased significantly. CONCLUSIONS: insulin therapy improves hepatic insulin sensitivity and slightly but significantly reduces liver fat content, independent of serum adiponectin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The associations between liver fat and hepatic insulin resistance have previously been reported by Bajaj et al, 62 who studied 14 type 2 diabetic patients, and by us in nondiabetic subjects 24,39 and type 2 diabetic patients treated with insulin. 36,38”
From Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. (2008) · cites this paper as [36]
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Adiponectin and Adiponectin Receptors
Kadowaki, T., & Yamauchi, T. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0005 · Cited by 2,634
Assessment of fat-free mass using bioelectrical impedance measurements of the human body
Lukaski, H., Johnson, P., Bolonchuk, W., & Lykken, G. (1985) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/41.4.810 · Cited by 1,896
The theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,604
Szczepaniak, L. S., Nurenberg, P., Leonard, D. S., Browning, J. D., Reingold, J. S., Grundy, S. M., Hobbs, H. H., & Dobbins, R. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,573
Lewis, G. F., Carpentier, A. C., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,370
Yu, J. G., Javorschi, S., Hevener, A. L., Kruszynska, Y. T., Norman, R. A., Sinha, M. K., & Olefsky, J. M. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2968 · Cited by 726
Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo
Szczepaniak, L. S., Babcock, E. E., Schick, F., Dobbins, R. L., Garg, A., Burns, D. K., McGarry, J. D., & Stein, D. T. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.5.e977 · Cited by 688
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1210/jcem.87.7.8638 · DOI · Paper page
Cited by
Sorted by citations
Items 101–141 of 141
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 9
Gao, F., Zafar, M. I., Ai, X., & Shafqat, R. A. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s75602 · Cited by 8
“Insulin is an effective treatment for lowering abnormal blood glucose levels and can also postpone the development of insulin resistance.(2) A good understanding of the physiology and pharmacokinetics of insulin will ensure a better treatment outcome.”
Lundholm, M. D., Bena, J., Zhou, K., Tsushima, Y., & Kashyap, S. R. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108405 · Cited by 7
Scheen, A. J. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100145 · Cited by 7
Karásek, D., Vaverková, H., Halenka, M., Jackuliaková, D., Fryšák, Z., & Novotný, D. (2011) · Biomedical Papers · doi:10.5507/bp.155.2011.002 · Cited by 7
Han, Y., Shin, Y. C., Kim, A., Kwon, E., & Choi, M. (2021) · Journal of Medicinal Food · doi:10.1089/jmf.2021.k.0070 · Cited by 6
“37 The insulin requirement is closely related to hepatic fat content, it is expected that patients with NAFLD need more insulin to improve glycemic control than those without NAFLD.”
Non‐Alcoholic Fatty Liver Disease
Day, C. P. (2010) · doi:10.1002/9781444314403.ch29 · Cited by 6
Hurjui, D. M., Niță, O., Graur, L. I., Popescu, D. Ş., Mihalache, L., Huţanaşu, C., & Graur, M. (2012) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/v10255-012-0037-x · Cited by 4
“In humans, exogenous insulin therapy decreases liver fat content significantly, suggesting that hyperinsulinemia may be a consequence rather than a cause [14].”
BackgroundScheen, A. J. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2252333 · Cited by 4
“Insulin therapy in T2DM increases hepatic insulin sensitivity while only marginally reducing liver fat level [60].”
BackgroundAlbai, O., Braha, A., Timar, R. Z., Lazăr, S., Popescu, S. D., & Timar, B. (2025) · Medicina · doi:10.3390/medicina61101850 · Cited by 4
Pusl, T., Rust, C., & Parhofer, K. G. (2009) · Der Diabetologe · doi:10.1007/s11428-009-0457-2 · Cited by 4
Kostitska, I. O., Protas, N., & Petrovska, L. (2023) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2023-5-01 · Cited by 3
Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1 Diabetes
Janssen, J. A. M. J. L., Llauradó, G., Varewijck, A. J., Groop, P., Forsblom, C. M., Fernández‐Veledo, S., van den Dungen, E. S. R., Vendrell, J. J., Hofland, L. J., & Yki‐Järvinen, H. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00892 · Cited by 3
Abnormalities in lipoprotein kinetics in Type 2 diabetes
Vergès, B. L. (2010) · Clinical Lipidology · doi:10.2217/clp.10.2 · Cited by 2
Safi, S., Hommadi, A., Moudden, K., Ajdi, F., Hassikou, H., Messayeh, T., Baaj, M. E., Nazzi, M., & Hadri, L. (2012) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2011.04.003 · Cited by 2
Tang, S. Y., Cheah, I. K.-M., Ng, P. E., Hoi, A., & Jenner, A. M. (2014) · ISRN Oxidative Medicine · doi:10.1155/2014/659029 · Cited by 2
Traitement de la stéatose et de la stéatohépatite non alcoolique par les traitements antidiabétiques
Vergès, B. L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30166-9 · Cited by 2
Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L., Lundbom, N. M. I., Rissanen, A., Ridderstråle, M., & Groop, L. (2009) · Cited by 2
Fígado Gordo Não Alcoólico: Revisão da Literatura
Matos, L. C. (2017) · Gazeta Médica · doi:10.29315/gm.v4i1.36 · Cited by 2
Milkarizi, N., Barghchi, H., Nematizade, M., Belyani, S., Bahari, H., Rajabzade, F., Kheyrabadi, S. Y. G., Razavidarmian, M., & Nematy, M. (2026) · Health Science Reports · doi:10.1002/hsr2.72681 · Cited by 1
Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie
Apostolopoulou, M., & Roden, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_20 · Cited by 1
The Role of Glutamate Signalling In Diabetic Neuropathy
Hussain, N. (2014) · Cited by 1
Effects of treatment of NAFLD on the metabolic syndrome
Yki‐Järvinen, H. (2016) · Wiley eBooks · doi:10.1002/9781118924938.ch21 · Cited by 1
Hodson, K. K. (2019) · Cited by 1
Tang, A., RABASA-LHORET, R. P. R., Castel, H., Wartelle‐Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A., de Guise, J. A., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1091 · Cited by 1
“(4) reported a 3% absolute liver fat fraction decrease despite a 3-kg weight gain in their cohort.”
BackgroundDiabetes and NAFLD: Why is the Connection Important?
Bugianesi, E. (2013) · doi:10.1002/9781118556153.ch6
Nogueira, K. C. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2012.tde-27072012-155318
LIVER FAT IN THE METABOLIC SYNDROME AND TYPE 2 DIABETES
Kotronen, A. (2008) · Työväentutkimus Vuosikirja
Taylor, R. (2013)
Non-alcoholic steatohepatitis: metabolic syndrome of the liver
Day, C. P. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8767-7_17
Non-alcoholic steatohepatitis — therapeutic interventions
Day, C. (2009) · Springer eBooks · doi:10.1007/978-90-481-2759-7_14
Manchiero, C. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2017.tde-03052017-151729
Effects of Butter and Phytanic acid intake on metabolic parameters and T-cell polarization
Drachmann, T., Hellgren, L. I., & Brix, S. (2012)
Kotronen, A., Juurinen, L., Tiikkainen, M., & Vehkavaara, S. (2008)
NOVEL THERAPEUTIC USE OF INSULIN AND VITAMIN E IN (NAFLD) USING FATTY LIVER INDUCED RATS.
Badawy, I., Mohsen, M., Ahmed, A., Mahmoud, S., Saeed, A., Atef, A., Rabea, A., Mauric, M., & Zlat, B. (2018) · International Journal of Advanced Research · doi:10.21474/ijar01/7113
“In studies to date, intensive insulin therapy has not had anysignificant change in the size of the subcutaneous and visceral fat depots in patients withtype 2 diabetes (Kotronen et al., 2007 and Elsayed et al., 2007).”
BackgroundTakhman, W., Nour, M. A., Merai, A., Saudi, L., Maree, M., Ghanem, A. A., Hamaida, J. M., & Damiri, B. (2023) · Palestinian medical and pharmaceutical journal/Palestinian medical & pharmaceutical journal · doi:10.59049/2790-0231.1250
İnsülin 100 Yıllık Mucize Hormon
Cerit, E. T., Barlas, T., Atalar, K., Bahçelioğlu, M., Kaplanoğlu, G. T., Seymen, C. M., Erdem, H. B., Ergün, M. A., Demir, Ö., Gülbahar, Ö., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.871
Rebelos, E., & Kounatidis, D. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00273-9
Jensen, V. S., Fledelius, C., Zachodnik, C., Damgaard, J., Nygaard, H., Tornqvist, K. S., Kirk, R. K., Viuff, B. M., Wulff, E. M., Lykkesfeldt, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14052747
Nocturnal insulin resistance and reduced insulin availability in human MASLD
Luukkonen, P. K. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.05.014
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.06.013
Metadata
- Authors
- Juurinen, L., Tiikkainen, M., Häkkinen, A.-M., Hakkarainen, A., & Yki-Järvinen, H.
- ORCID
- Hakkarainen, Antti
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2007-03
- Volume
- 292
- Issue
- 3
- Pages
- E829-E835
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2062583781
- Cited by
- 141
- References
- 54
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 2 · 2023: 6 · 2022: 6 · 2021: 10 · 2020: 4 · 2019: 6 · 2018: 3 · 2017: 10 · 2016: 11 · 2015: 7 · 2014: 10 · 2013: 8 · 2012: 9
- FWCI
- 5.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Physiology-Endocrinology and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin therapy, type 2 diabetes, hepatic insulin sensitivity, liver fat, hepatic glucose production, basal insulin, metformin, fat-free mass, free fatty acids, adiponectin, weight gain, hyperinsulinemic-euglycemic clamp, 1H NMR
- MeSH terms
- Alanine Transaminase, Basal Metabolism, Diabetes Mellitus, Type 2, Drug Combinations, Fatty Acids, Nonesterified, Glucose, Humans, Insulin, Insulin Resistance, Lipids, Liver, Metformin, Middle Aged, Oxidation-Reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
